<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576456</url>
  </required_header>
  <id_info>
    <org_study_id>awxg2018</org_study_id>
    <nct_id>NCT03576456</nct_id>
  </id_info>
  <brief_title>Sedative Premedication in Coronary Angiography</brief_title>
  <official_title>Sedative Premedication in Coronary Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the possible positive effect of sedative premedication prior to coronary
      angiography in regards to pain and anxiety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary angiography is an invasive procedure that can cause patient discomfort. Sedative
      premedication before coronary angiography could be used to reduce anxiety and pain, but
      evidence is lacking. Previous trials were predominantly conducted in men and in coronary
      interventions with femoral access. Recently, radial access has become the preferred route for
      performing coronary angiograms (RIVAL trial) In this setting, sedative premedication could be
      of interest to reduce radial spasms, patient anxiety and pain.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo controlled, double blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>preprocedural anxiety: visual analogue scale</measure>
    <time_frame>Assessed before the coronary angiography</time_frame>
    <description>anxiety prior to coronary angiography. Assessed before the procedure through a visual analogue scale for anxiety (VAS-A). The VAS is a visual scale ranging from 0 to 100 with 0 begin no anxiety at all and 100 begin extreme anxiety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>periprocedural pain: visual analogue scale</measure>
    <time_frame>Assessed after the coronary angiography, within 4 hours.</time_frame>
    <description>pain during to coronary angiography. Assessed after the procedure through a visual analogue scale for pain. The VAS scale is a visual scale ranging from 0 (no pain) to 100 (extreme pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>radial spasm</measure>
    <time_frame>during procedure</time_frame>
    <description>spasm of the radial artery as experienced by operator. There is no precise measurement up until today.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular site access complication</measure>
    <time_frame>during procedure</time_frame>
    <description>need to switch to femoral access, assessed by the operator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Coronary Angiography</condition>
  <condition>Sedative Premedication</condition>
  <arm_group>
    <arm_group_label>Alprazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive alprazolam 0.5 mg 1 hour prior to coronary angiography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo 1 hour prior to coronary angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam 0.5 mg</intervention_name>
    <description>receive alprazolam prior to angio</description>
    <arm_group_label>Alprazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>receive placebo prior to angio</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective coronary angiography

        Exclusion Criteria:

          -  planned PCI

          -  use of sedative medication at home

          -  use of alcohol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danny Schoors, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of service</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adriaan Wilgenhof, MD</last_name>
    <phone>003224776009</phone>
    <email>adriaan.wilgenhof@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Adriaan Wilgenhof</name>
      <address>
        <city>Brussels</city>
        <state>Jette</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Adriaan Wilgenhof, MD</last_name>
      <phone>003224776009</phone>
      <email>adriaan.wilgenhof@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xavier Galloo, MD</last_name>
      <phone>003224776009</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>October 11, 2018</last_update_submitted>
  <last_update_submitted_qc>October 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Wilgenhof Adriaan</investigator_full_name>
    <investigator_title>Medical Doctor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>coronary angiography</keyword>
  <keyword>premedication</keyword>
  <keyword>pain</keyword>
  <keyword>anxiety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>within 1 month, during 1 year</ipd_time_frame>
    <ipd_access_criteria>researcher</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

